| 1 |
33429148 | CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. | 2021 Mar |
2 |
| 2 |
33857297 | Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods. | 2021 Sep 2 |
1 |
| 3 |
34159337 | Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen. | 2021 Jun 15 |
1 |
| 4 |
34344439 | Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. | 2021 Aug 3 |
1 |
| 5 |
34382727 | miR-221 confers lapatinib resistance by negatively regulating p27kip1 in HER2-positive breast cancer. | 2021 Oct |
2 |
| 6 |
34435487 | Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer. | 2021 Sep 9 |
1 |
| 7 |
34589134 | Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer. | 2021 |
2 |
| 8 |
32563955 | Lower concentrations of curcumin inhibit Her2-Akt pathway components in human breast cancer cells, and other dietary botanicals potentiate this and lapatinib inhibition. | 2020 Jun |
1 |
| 9 |
32601199 | Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. | 2020 Jul 14 |
1 |
| 10 |
30343043 | Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. | 2019 Feb |
1 |
| 11 |
31092430 | Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways. | 2019 May |
2 |
| 12 |
29223420 | HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. | 2018 Feb |
1 |
| 13 |
29271513 | Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. | 2018 Jul |
1 |
| 14 |
29453318 | Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. | 2018 May |
1 |
| 15 |
29845287 | Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer. | 2018 Jul |
3 |
| 16 |
30591093 | HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. | 2018 Dec |
2 |
| 17 |
27154770 | Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. | 2017 Mar |
1 |
| 18 |
28243326 | The research on lapatinib in autophagy, cell cycle arrest and epithelial to mesenchymal transition via Wnt/ErK/PI3K-AKT signaling pathway in human cutaneous squamous cell carcinoma. | 2017 |
3 |
| 19 |
28744398 | Kinase inhibitors of HER2/AKT pathway induce ERK phosphorylation via a FOXO-dependent feedback loop. | 2017 |
2 |
| 20 |
28759294 | Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. | 2017 Aug 18 |
1 |
| 21 |
28938602 | Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. | 2017 Aug 29 |
4 |
| 22 |
29156708 | A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. | 2017 Oct 17 |
2 |
| 23 |
29169418 | [Mechanism underlying inhibition of proliferation and promotion of apoptosis by lapatinib in HL60 cells]. | 2017 Oct |
1 |
| 24 |
26621843 | The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. | 2016 Jan 19 |
2 |
| 25 |
27157613 | MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. | 2016 Dec 1 |
1 |
| 26 |
27256378 | Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. | 2016 Sep |
1 |
| 27 |
27293993 | Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. | 2016 |
1 |
| 28 |
27633099 | Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway. | 2016 Nov |
4 |
| 29 |
25157953 | HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. | 2015 Apr 1 |
1 |
| 30 |
25449780 | Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. | 2015 Jan 28 |
2 |
| 31 |
25590338 | Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. | 2015 |
2 |
| 32 |
25678800 | Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. | 2015 |
1 |
| 33 |
26063481 | Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1. | 2015 Aug |
2 |
| 34 |
26114862 | The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes. | 2015 |
1 |
| 35 |
26134366 | Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates. | 2015 |
1 |
| 36 |
26152725 | Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival. | 2015 Aug 28 |
2 |
| 37 |
26181325 | Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. | 2015 |
3 |
| 38 |
26296355 | Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas. | 2015 Dec 15 |
2 |
| 39 |
26557906 | Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib. | 2015 Nov |
1 |
| 40 |
23948998 | Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. | 2014 |
1 |
| 41 |
24172910 | Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro. | 2014 Jan |
3 |
| 42 |
24200972 | Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. | 2014 |
2 |
| 43 |
24754246 | Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. | 2014 Jul |
1 |
| 44 |
24820961 | A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. | 2014 Sep |
3 |
| 45 |
24916181 | A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. | 2014 Jul |
1 |
| 46 |
24973425 | Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. | 2014 Sep 1 |
1 |
| 47 |
23229346 | Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells. | 2013 Feb |
1 |
| 48 |
23292912 | ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. | 2013 Jul |
1 |
| 49 |
23794518 | Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. | 2013 Dec |
1 |
| 50 |
23811285 | RON confers lapatinib resistance in HER2-positive breast cancer cells. | 2013 Oct 28 |
1 |